- Investing Ideas
- /
- Swiss Top Stock Picks from Analysts
Swiss Top Stock Picks from Analysts
Results
16
Companies which are more than 50% undervalued based on analyst price target.
16 companies
naturenergie holding
Market Cap: CHF 1.1b
Through its subsidiaries, engages in the production, distribution, and sale of electricity under the Naturenergie brand in Switzerland and internationally.
NEAG
CHF 32.50
7D
-0.9%
1Y
-2.4%
Basilea Pharmaceutica
Market Cap: CHF 672.1m
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
BSLN
CHF 54.70
7D
-0.9%
1Y
31.8%
R&S Group Holding
Market Cap: CHF 588.4m
Manufactures and supplies electrical infrastructure products the United Kingdom, Switzerland, Ireland, Italy, Poland, and the Middle East.
RSGN
CHF 15.82
7D
-0.3%
1Y
-20.3%
Cicor Technologies
Market Cap: CHF 559.5m
Develops, and manufactures electronic components, devices, and systems worldwide.
CICN
CHF 127.00
7D
2.4%
1Y
111.7%
medmix
Market Cap: CHF 458.8m
Designs, produces, and sells high-precision devices and services in Switzerland and internationally.
MEDX
CHF 11.24
7D
2.0%
1Y
23.0%
Vetropack Holding
Market Cap: CHF 436.1m
Provides glass packaging products for the food and beverage industry.
VETN
CHF 22.00
7D
1.9%
1Y
-13.0%
Schweiter Technologies
Market Cap: CHF 362.2m
Develops, produces, and sells composite materials and solutions in lightweight construction in Europe, the Americas, Asia, and internationally.
SWTQ
CHF 253.00
7D
1.6%
1Y
-39.2%
MindMaze Therapeutics Holding
Market Cap: CHF 289.9m
Develops and operates the MindMaze platform that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology.
MMTX
CHF 1.90
7D
-15.9%
1Y
n/a
DocMorris
Market Cap: CHF 289.2m
Operates as an online pharmacy, telemedicine, and healthcare company in Switzerland and internationally.
DOCM
CHF 5.95
7D
5.7%
1Y
-70.1%
Santhera Pharmaceuticals Holding
Market Cap: CHF 168.5m
A specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia.
SANN
CHF 12.60
7D
-2.2%
1Y
-12.9%
BioVersys
Market Cap: CHF 142.7m
A clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria.
BIOV
CHF 24.40
7D
-2.4%
1Y
n/a
lastminute.com
Market Cap: CHF 138.6m
Operates in the online travel industry providing dynamic holiday packages in Italy, Spain, the United Kingdom, France, Germany, and internationally.
LMN
CHF 13.00
7D
2.4%
1Y
-22.2%
Molecular Partners
Market Cap: CHF 126.6m
A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
MOLN
CHF 3.39
7D
-1.2%
1Y
-23.6%
Curatis Holding
Market Cap: CHF 60.4m
Engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases.
CURN
CHF 12.00
7D
3.9%
1Y
-4.8%
Swiss Estates
Market Cap: CHF 10.4m
Engages in investing in the real estate properties in Switzerland.
SEAN
CHF 2.40
7D
0%
1Y
n/a
Asmallworld
Market Cap: CHF 10.0m
Operates a digital travel and lifestyle ecosystem worldwide.
ASWN
CHF 0.69
7D
6.2%
1Y
-50.0%